Proteologics is a biopharmaceutical company exploiting the UBIQUITIN system for the discovery and development of novel therapeutics. Drs. Avram Hershko and Aaron Ciechanover, - 2004 Nobel Prize in Chemistry laureates for the discovery of the ubiquitin system - lead our distinguished scientific advisory board. Proteologics world-class knowledge, supported by a unique target and drug discovery platform, is being used to unveil the role of ubiquitin in pathologies with the goal of developing ubiquitin system targeted drugs.

Proteologics focuses primarily on discovering inhibitors for specific ubiquitin enzymes - E3 ligases - and their interacting proteins. These enzymes, which control the regulation of protein breakdown, are known to play key roles in a variety of processes in the cells. E3's are believed to offer novel drug targets for many types of cancer, metabolic disease, viral infections and CNS related disorders. In 2009 Proteologics has three active drug discovery programs backed by venture capital funding and collaboration with strategic partner. The company is currently identifying novel drugs to provide more effective treatment against metastatic cancers. In parallel, the company is developing therapeutic agents to interfere at specific ubiquitin pathway sites relevant to a number of cancer tumor types. All three projects are developed in collaboration with Teva Pharmaceutical Industries Ltd under collaboration and licensing agreements. In January 2010 the company will initiate two drug discovery programs. These programs will target specific components of the ubiquitin system that offers new approaches for the development of innovative medicines to different types of cancer.

 

.